Neoplasms

All Conditions

Immune System Diseases

Blood and Lymph Conditions

Rare Diseases

Neoplasms, Plasma Cell

Plasmacytoma

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Immunoproliferative Disorders

Antineoplastic Agents

Antirheumatic Agents

All Drugs and Chemicals

Cyclophosphamide

Fludarabine

Fludarabine phosphate

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Patients will be treated with Auto CAR-T cells

Auto CAR-T

Cyclophosphamide,Fludarabine

Leukapheresis

Jianqiang Li, PhD & MD

Lihong Liu, PhD & MD

Baoen Shan, PhD & MD

This study is a multi-center, non-randomized, single-arm, open clinical trial.

A single car consists of scFv, hinge region, transmembrane region, costimulatory domain and zeta subunit of CD3.Prior to CAR-T cell infusion, the patients will be subjected to preconditioning treatment. After CAR-T cell infusion, the patients will be evaluated for adverse reactions and efficacy.

Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors

To evaluate the possible adverse events occurred within first one month after CAR-T infusion, including the incidence and severity of symptoms such as cytokine release syndrome and neurotoxicity

Remission Rate including complete remission (CR), partial remission (PR), objective response (ORR = CR + PR), disease stability (SD), disease progression (PD) and unresponsive (NR)

Hebei Medical University Fourth Hospital

Hebei Senlang Biotechnology Inc., Ltd.

Leukemia

Lymphoma

Lymphosarcoma

Jianqiang Li, PhD&MD

Lian Jiang, MD

This is an open, single-arm, prospective，clinical study to evaluate efficacy and safety of Auto CAR-T cell injection in the treatment of recurrent or refractory Hematopoietic and Lymphoid Tissue Tumors in Children

Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children

Remission Rate including complete remission(CR)、partial response(PR)、No remission(NR)、progressive disease(PD)

Lymphoma, Non-Hodgkin

Lymphatic Diseases

This study is a multicenter, non randomized, single arm, open clinical trial. The selected disease was relapsed / refractory NHL, and the disease was classified into highly aggressive lymphoma, invasive lymphoma and inert lymphoma; Highly invasive NHL included Burkitt lymphoma (BL), lymphoblastic lymphoma (LBL), high-grade B-cell lymphoma, etc; Invasive NHL includes diffuse large B-cell lymphoma, mantle cell lymphoma and peripheral T-cell lymphoma; Inert NHL contains follicular lymphoma, small lymphocytic lymphoma and marginal zone lymphoma.

A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors	NCT04665076	Plasma Cell Tum...	Auto CAR-T Cyclophosphamid... Leukapheresis	14 Years - 75 Years	Hebei Senlang Biotechnology Inc., Ltd.
Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children	NCT04610125	Leukemia Lymphoma	Auto CAR-T Cyclophosphamid... Leukapheresis	1 Year - 18 Years	Hebei Senlang Biotechnology Inc., Ltd.
Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children	NCT04610125	Leukemia Lymphoma	Auto CAR-T Cyclophosphamid... Leukapheresis	1 Year - 18 Years	Hebei Senlang Biotechnology Inc., Ltd.
A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma	NCT04666168	Non-hodgkin's L...	Auto CAR-T Cyclophosphamid... Leukapheresis	14 Years - 75 Years	Hebei Senlang Biotechnology Inc., Ltd.

Spots Global Cancer Trial Database for cyclophosphamide,fludarabine